Advertisement

Topics

CytomX Wins $15M Milestone Payment from AbbVie for Cancer Probody–Drug Conjugate

06:24 EDT 29 Jun 2017 | Genetic Engineering News

CytomX Therapeutics said today it will receive a $15 milestone payment from AbbVie for advancing a cancer-fighting Probody™–drug conjugate (PDC) being developed by the companies into Good Laboratory Practice ( GLP) toxicology studies toward filing an Investigational New Drug (IND) application next year. CX-2029 is a PDC designed to target CD71, also known as transferrin receptor 1 (TfR1), on tumor cells while sparing healthy cells by localizing the drug candidate’s activity primarily to cancer tissue. CD71 is highly and homogeneously expressed on many solid and blood tumor types. While that would make CD71 an ideal target for antibody–drug conjugate strategies, the target is present on most normal cells—a challenge the companies say can be addressed by developing a therapeutic based on CytomX’s Probody platform. Probody therapeutics are designed to remain inactive until they are activated by proteases in the tumor microenvironment. According to CytomX, the therapeutics ...

Original Article: CytomX Wins $15M Milestone Payment from AbbVie for Cancer Probody–Drug Conjugate

NEXT ARTICLE

More From BioPortfolio on "CytomX Wins $15M Milestone Payment from AbbVie for Cancer Probody–Drug Conjugate"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...